Figure 4.
Molecular risk of CNL/aCML. (A) shows the percentage and number of patients in each group and (B) the survival of different groups (curves under a Cox model adjusted by age, sex, and leukocyte count). Group 1 (red, reference group): no high-risk mutations or mutated CSF3R; group 2 (blue, HR 4.5, P = .192): mutated CSF3R but no high-risk mutations; group 3 (green, HR 18.0, P = .012): patients with high-risk mutations but unmutated CSF3R; group 4 (orange, HR 15.6, P = .003): patients mutated CSF3R and high-risk mutations. High-risk mutations include CBL, CEBPA, EZH2, NRAS, TET2, and U2AF1.

Molecular risk of CNL/aCML. (A) shows the percentage and number of patients in each group and (B) the survival of different groups (curves under a Cox model adjusted by age, sex, and leukocyte count). Group 1 (red, reference group): no high-risk mutations or mutated CSF3R; group 2 (blue, HR 4.5, P = .192): mutated CSF3R but no high-risk mutations; group 3 (green, HR 18.0, P = .012): patients with high-risk mutations but unmutated CSF3R; group 4 (orange, HR 15.6, P = .003): patients mutated CSF3R and high-risk mutations. High-risk mutations include CBL, CEBPA, EZH2, NRAS, TET2, and U2AF1.

Close Modal

or Create an Account

Close Modal
Close Modal